College of Pharmacy, University of Hawaii, Hilo, Hawaii 96720, USA.
Anticancer Res. 2010 Dec;30(12):4873-82.
In the search for agents with cancer chemopreventive potential, 14-chloromethyl-12H-5,11a-diazadibenzo[b,h]fluoren-11-one (compound 1), originally synthesized as a potential topoisomerase I inhibitor, and 2,4-dibromo-1-hydroxyphenazine (compound 2), an analog of a substance found in the marine bacteria Streptomyces CNS284, were found to significantly enhance NADP(H):quinone oxidoreductase 1 (QR1), glutathione S-transferase (GST), and glutathione (GSH) levels in cell culture. However, following a short-term absorption study, analyses of livers from the treatment groups did not reveal a significant increase in QR1 or GST activity, or GSH levels. This was consistent with RT-PCR analyses of tissue samples. The compounds were absorbed, as judged by LC/MS analyses of serum and tissue samples, although levels were well below the concentrations required to mediate in vitro responses. Metabolites of compound 2 formed in vitro by human liver microzones were characterized using high resolution tandem mass spectrometry. In sum, the in vivo activity of these compounds appears to be diminished by low bioavailability, but this experimental approach indicates the importance of systematic biomarker investigation.
在寻找具有癌症化学预防潜力的药物时,14-氯甲基-12H-5,11a-二氮杂二苯并[b,h]荧烯-11-酮(化合物 1),最初被合成作为一种潜在的拓扑异构酶 I 抑制剂,和 2,4-二溴-1-羟基吩嗪(化合物 2),一种在海洋细菌链霉菌 CNS284 中发现的物质的类似物,被发现可显著增加细胞培养物中的 NADP(H):醌氧化还原酶 1(QR1)、谷胱甘肽 S-转移酶(GST)和谷胱甘肽(GSH)水平。然而,在短期吸收研究之后,对治疗组肝脏的分析并未显示 QR1 或 GST 活性或 GSH 水平显著增加。这与组织样本的 RT-PCR 分析一致。尽管通过 LC/MS 分析血清和组织样本判断化合物被吸收,但水平远低于介导体外反应所需的浓度。用人肝微区在体外形成的化合物 2 的代谢物使用高分辨率串联质谱进行了表征。总之,这些化合物的体内活性似乎由于生物利用度低而降低,但这种实验方法表明系统生物标志物研究的重要性。